Equities Analysts Set Expectations for Novavax Q2 Earnings

Novavax, Inc. (NASDAQ:NVAX) – Analysts at B. Riley increased their Q2 2025 earnings estimates for Novavax in a report issued on Thursday, February 20th. B. Riley analyst M. Mamtani now expects that the biopharmaceutical company will post earnings of $0.67 per share for the quarter, up from their previous forecast of $0.65. The consensus estimate for Novavax’s current full-year earnings is ($1.46) per share. B. Riley also issued estimates for Novavax’s FY2026 earnings at $2.05 EPS, FY2027 earnings at $1.49 EPS, FY2028 earnings at $0.96 EPS and FY2029 earnings at $1.62 EPS.

Separately, HC Wainwright reiterated a “buy” rating and issued a $19.00 price target on shares of Novavax in a report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Novavax has an average rating of “Hold” and a consensus price target of $17.83.

Novavax Trading Down 1.2 %

Novavax stock opened at $7.92 on Friday. The firm’s fifty day moving average is $8.68 and its 200 day moving average is $10.14. Novavax has a 12-month low of $3.81 and a 12-month high of $23.86.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Sanofi purchased a new stake in shares of Novavax during the 4th quarter valued at $55,319,000. Deep Track Capital LP bought a new position in Novavax during the fourth quarter valued at about $16,080,000. State Street Corp increased its holdings in Novavax by 26.7% during the third quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company’s stock worth $97,099,000 after buying an additional 1,621,772 shares during the last quarter. Shah Capital Management raised its position in Novavax by 13.6% in the fourth quarter. Shah Capital Management now owns 11,148,846 shares of the biopharmaceutical company’s stock worth $89,637,000 after acquiring an additional 1,333,305 shares during the period. Finally, Two Sigma Advisers LP boosted its stake in Novavax by 48.9% in the third quarter. Two Sigma Advisers LP now owns 1,999,400 shares of the biopharmaceutical company’s stock valued at $25,252,000 after acquiring an additional 656,900 shares during the last quarter. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Insider Transactions at Novavax

In other Novavax news, Director Rachel K. King sold 4,150 shares of Novavax stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $9.02, for a total transaction of $37,433.00. Following the transaction, the director now owns 14,770 shares of the company’s stock, valued at $133,225.40. This trade represents a 21.93 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James F. Young sold 5,400 shares of the company’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $8.00, for a total value of $43,200.00. Following the completion of the transaction, the director now directly owns 51,760 shares of the company’s stock, valued at approximately $414,080. This represents a 9.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 14,150 shares of company stock worth $119,641 in the last quarter. 1.00% of the stock is currently owned by corporate insiders.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.